


Industry-Sponsored Symposium

A New Frontier: Emerging Biomarkers and Antibody-Drug Conjugates in Advanced NSCLC

Saturday 06 August 2022, 15:45–16:45 CEST, Hall C8



Sanofi are pleased to invite you to this Industry Sponsored Symposium, during which we will:

- Learn about recent developments in ADC technology
- Become familiar with emerging biomarkers in NSCLC
- Learn about the clinical development of ADCs for advanced NSCLC

Click to save this date in your calendar and further details will be provided soon.

Click here to save the date



Dr. David Gandara (CHAIR)UC Davis Comprehensive
Cancer Center, CA, USA



Dr. Ming TsaoPrincess Margaret Cancer Centre and University of Toronto, Canada



Dr. Alastair Greystoke Newcastle University and Newcastle upon Tyne NHS Foundation Trust, Newcastle, UK

Time (CEST)	Session	Faculty
15:45-16:00	Welcome and Overview of the Current Treatment Algorithms for Patients with NSCLC	Dr. David Gandara (Chair)
16:00-16:15	What, How, and Where Do We Test Emerging Biomarkers?	Dr. Ming Tsao
16:15-16:30	Emerging and Novel Therapies in Patients without Driver Mutations	Dr. Alastair Greystoke
16:30-16:40	Roundtable Discussion	All faculty
16:40-16:45	Final Remarks	Dr. David Gandara

MAT-GLB-2202527-V1.0; Date of approval: June 2022